CINCINNATI--(BUSINESS WIRE)--Jan. 14, 2014--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the opening of an
office in Singapore to support and grow the Bioline business in
Singapore and in Asia.
With the opening of the new office; Bioline will provide direct sales,
technical support, and training to its existing customers and can also
offer a same-day delivery to many of its Singapore-based customers. The
investment has included the creation of several Sales and Support
positions within the Bioline Singapore office to underpin the increase
in service levels. The new location will also be key in the future
development of opportunities in the region and provide on-going support
to Life Science researchers within Asia.
Marco Calzavara, President of Bioline, commented, “The opening of the
Singapore office marks a significant milestone for Bioline, allowing us
to support our customers in Singapore with enhanced levels of service
for our high-performance PCR products. In addition, Singapore shall
serve as a hub for Bioline activities in Asia; supporting the needs of
our growing customer-base in Asia.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We
are delighted to open the new Bioline office in Singapore. Our customers
can now call us locally, place orders, and receive the goods the same
day. This is a further demonstration of our commitment to our life
science customers and to bringing innovation and quality products; such
as the highly popular SensiFASTTM Real-Time kits and the
proven MyTaqTM DNA Polymerase to the research laboratory,
clinical diagnostic laboratories, and biotechnology companies.”
Bioline supplies customers in over 30 countries worldwide and serves a
large and growing PCR reagents market. The Asian market is projected to
grow significantly over the next three to five years. The opening of the
Singapore office is intended to provide a platform for Bioline to expand
into these fast growing markets and to grow its market share globally.
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life
science company that develops, manufactures, markets and distributes a
broad range of innovative diagnostic test kits, purified reagents and
related products and offers biopharmaceutical enabling technologies.
Utilizing a variety of methods, these products and diagnostic tests
provide accuracy, simplicity and speed in the early diagnosis and
treatment of common medical conditions, such as gastrointestinal, viral
and respiratory infections. Meridian’s diagnostic products are used
outside of the human body and require little or no special equipment.
The Company's products are designed to enhance patient well-being while
reducing the total outcome costs of healthcare. Meridian has strong
market positions in the areas of gastrointestinal and upper respiratory
infections, serology, parasitology and fungal disease diagnosis. In
addition, Meridian is a supplier of rare reagents, specialty biologicals
and related technologies used by biopharmaceutical companies engaged in
research for new drugs and vaccines. The Company markets its products
and technologies to hospitals, reference laboratories, research centers,
diagnostics manufacturers and biotech companies in more than 60
countries around the world. The Company’s shares are traded on NASDAQ’s
Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
For more information about Bioline, please
more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com.
more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com.
L. Eberly, email@example.com
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
Richard L. Eberly, 513-271-3700